Among the most feared diagnoses in medicine, glioblastoma has long demanded invasive confirmation through surgical biopsy—a process as burdensome as the disease itself. Researchers from the University of Notre Dame and Australian institutions have now demonstrated that a few drops of blood, processed through a two-dollar biochip in under an hour, can detect the molecular signatures of this aggressive brain cancer with remarkable accuracy. The achievement does not yet replace the full diagnostic journey, but it opens a quieter, less violent door into early detection—one that science is only beg
New Blood Test Detects Brain Cancer in One Hour, But Specificity Remains Limited
A positive result signals something is wrong, but not what.
Mark
So this test can identify brain cancer from a drop of blood in an hour. That sounds like it could change how we diagnose glioblastoma.
Mimi
It's genuinely faster and less invasive than the current standard, which is a surgical biopsy. You're taking a tiny sample instead of drilling into someone's skull. But the test doesn't actually diagnose glioblastoma specifically—it detects a mutation that appears in glioblastoma and other cancers too.
Luke
Right. The EGFR mutation shows up in colorectal cancer, for instance. So a positive result tells you something is wrong, but not what.
Mimi
Exactly. And the researchers are clear about this in their paper. Some glioblastoma patients don't even have EGFR mutations, so the test would miss them entirely.
Mark
How many patients did they actually test this on?
Luke
Twenty with glioblastoma and ten healthy controls. That's a proof of concept, not a clinical validation. You need hundreds or thousands to establish whether this can reliably distinguish glioblastoma from other EGFR-driven cancers.
Mimi
They acknowledge that too. They're saying this is an important step, but they need to build a much larger library of biomarker profiles across different cancer types and disease stages.
Mark
So what's the actual value right now?
Mimi
The technology itself is valuable. A two-dollar biochip that can detect these vesicles without preprocessing—that's elegant. It could be useful for monitoring cancer patients or screening high-risk populations. But as a standalone diagnostic for glioblastoma? Not yet.
Luke
And we should be clear: the test showed excellent accuracy in their small sample, but "excellent accuracy" in detecting a biomarker is different from "excellent accuracy" in diagnosing a disease. Those are two different claims.
Mark
Fair point. So this is promising, but not ready for the clinic.
Mimi
Not as a definitive diagnostic. But it's the kind of foundational work that makes better diagnostics possible down the line.
The Pulse
- Glioblastoma kills quickly and diagnoses slowly, making every hour between symptom and confirmation a critical loss of ground.
- A $2 biochip with an electrokinetic sensor the size of a pen's ball tip can detect cancer-linked proteins in raw blood plasma within 60 minutes—no preprocessing, no surgical intrusion.
- In a trial of 30 individuals, the test outperformed all existing glioblastoma biomarkers, producing statistically robust results from a sample smaller than a raindrop.
- The test's Achilles heel is specificity: mutated EGFR proteins appear in colorectal and other cancers too, meaning a positive result points toward danger without naming it.
- Researchers are now calling for large-scale studies across hundreds of cancer patients to build a biomarker library that could one day tell not just that cancer is present, but which cancer and where.
Among the most feared diagnoses in medicine, glioblastoma has long demanded invasive confirmation through surgical biopsy—a process as burdensome as the disease itself. Researchers from the University of Notre Dame and Australian institutions have now demonstrated that a few drops of blood, processed through a two-dollar biochip in under an hour, can detect the molecular signatures of this aggressive brain cancer with remarkable accuracy. The achievement does not yet replace the full diagnostic journey, but it opens a quieter, less violent door into early detection—one that science is only beginning to push open.
A research team spanning the University of Notre Dame and several Australian institutions has developed a blood test capable of detecting glioblastoma—the most lethal and common form of brain cancer—in approximately one hour. The test requires only 100 microliters of blood, a few drops, and works by identifying mutated epidermal growth factor receptors (EGFRs) that glioblastoma cells shed into the bloodstream inside tiny structures called extracellular vesicles.
At the heart of the technology is a biochip costing less than two dollars. Its sensor, roughly the size of a ballpoint pen's ball, is coated with antibodies that bind to vesicles carrying the mutated proteins. When binding occurs, the blood plasma registers a sharp voltage shift—a negative charge that signals likely cancer presence. Crucially, the sensor works directly on untreated blood plasma, bypassing the preprocessing steps that introduce error and contamination in competing methods. The team reports it can detect exosome concentrations as low as 0.01 percent.
Initial testing on 20 confirmed glioblastoma patients and 10 healthy individuals yielded excellent accuracy and high statistical reproducibility, outperforming all existing diagnostic approaches for this cancer. The prototype is described as near turn-key—ready to deploy with minimal setup.
Yet the researchers are candid about what the test cannot do. EGFR mutations are not exclusive to brain cancer; they also appear in colorectal and other malignancies. A positive result confirms the presence of these mutations, not the presence of glioblastoma specifically. The test cannot locate the cancer, stage it, or even detect cases driven by non-EGFR genetic pathways—meaning some glioblastomas would be missed entirely.
What has been published in Communications Biology is therefore a proof of concept rather than a finished diagnostic tool. The team's next step is scaling the platform to test blood from hundreds or thousands of cancer patients, building a library of disease-specific biomarker signatures across different cancer types and stages. The ambition is a future in which a rapid, inexpensive blood draw can meaningfully narrow the diagnostic field—sparing patients the delay and trauma of surgical biopsy while guiding clinicians toward the right questions faster.
A team of researchers from the University of Notre Dame and Australian institutions has developed a blood test that can identify glioblastoma—the most aggressive and common form of brain cancer—in roughly an hour. The test requires only a tiny sample: 100 microliters of blood, about the volume of a few drops. It works by detecting mutated proteins called epidermal growth factor receptors, or EGFRs, that are overexpressed in glioblastoma cells and circulate in the bloodstream inside small packages called extracellular vesicles.
The innovation centers on a biochip that costs less than two dollars and contains a sensor roughly the size of a ballpoint pen's ball. The chip is coated with antibodies designed to bind to these vesicles when they carry the mutated EGFRs. When the binding occurs, a voltage shift happens in the blood plasma—a sharp negative charge that signals the likely presence of cancer. The technology was built specifically to exploit the physical properties of these vesicles, which are far larger than individual molecules and carry a weak electrical charge. Because the sensor works directly on untreated blood plasma without requiring any preprocessing to isolate the vesicles first, it avoids the noise and contamination that plague other diagnostic methods. The researchers say their electrokinetic sensor can detect exosome concentrations as low as 0.01 percent.
In initial testing, the team ran the biochip on blood samples from 20 patients with confirmed glioblastoma and 10 healthy individuals. The results showed excellent accuracy and a very low p value, meaning the findings were highly reproducible. The test outperformed all existing biomarkers and diagnostic approaches for glioblastoma detection. The developers describe the prototype as having "near turn-key functionality"—meaning it is ready to use with minimal setup.
But the breakthrough comes with significant limitations that the researchers themselves acknowledge. Mutated EGFRs are not unique to glioblastoma. The same mutations appear in colorectal cancers and other malignancies. This means a positive result on the test does not definitively prove someone has brain cancer; it only indicates the presence of EGFR mutations. The test also cannot identify which type of cancer is present, where in the body it is located, or how far the disease has progressed. Additionally, not all glioblastoma patients carry EGFR mutations—some forms of the disease are driven by entirely different genetic pathways. This means the test will miss some cases of brain cancer altogether.
To move toward a more specific diagnostic tool, the researchers say they need to study much larger groups of glioblastoma patients to identify which blood biomarkers distinguish brain cancer from other EGFR-linked diseases and from healthy individuals. They propose scaling up their platform to test untreated blood plasma from hundreds or thousands of cancer patients, building a library of disease-specific signatures at different stages of progression. The work was published in Communications Biology. What emerges from this research is not yet a definitive diagnostic test for glioblastoma, but rather a proof of concept for a faster, less invasive way to screen for cancer-associated biomarkers—one that could eventually help clinicians narrow down possibilities and guide further investigation.
Notable Quotes
Our electrokinetic sensor allows us to do things other diagnostics cannot. We can directly load blood without any pretreatment because our sensor is not affected by other particles or molecules.— Satyajyoti Senapati, biomolecular engineer, University of Notre Dame
Such an EGFR signature might not necessarily indicate the presence of glioblastoma specifically, and patients with glioblastoma can have non-EGFR driven forms of the disease.— Research team, published in Communications Biology
Want the full story?
Read the original at ScienceAlert ↗
Health & Medicine